Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells

Table 1 Cell viability of hypoxic human colorectal carcinoma cell lines

Cell line	Mutations	ABT-737	AZD8055	combo-Rx	p-value
HCT-116	KRAS, PIK3CA	89.4 ± 19.1	73.0 ± 10.9	46.1 ± 13.7	0.0016
HCT-15	KRAS, PIK3CA	92.7 ± 2.31	89.7 ± 3.79	68.0 ± 10.4	0.028
SW620	KRAS	80.6 ± 8.91	77.8 ± 13.4	28.0 ± 3.46	<0.001
SW480	KRAS	99.0 ± 3.46	71.0 ± 12.1	41.7 ± 8.39	0.026
HCC2998	KRAS	85.3 ± 6.41	96.0 ± 14.2	37.0 ± 8.37	<0.001
LoVo	KRAS	101 ± 10.3	64.0 ± 7.21	58.7 ± 8.50	0.45
RKO	BRAF, PIK3CA	95.0 ± 12.8	65.3 ± 3.79	68.3 ± 5.03	0.46
KM20L2	BRAF	100 ± 4.62	90.9 ± 7.38	80.7 ± 6.63	0.019
WiDr	BRAF	98.3 ± 1.71	99.0 ± 3.46	68.7 ± 21.6	0.074
HT-29	BRAF	97.3 ± 7.48	86.0 ± 8.54	79.0 ± 11.4	0.44
CO-115	BRAF	86.3 ± 2.89	69.7 ± 2.52	58.7 ± 2.52	0.0059
Caco-2	wild-type	90.4 ± 17.0	60.1 ± 15.3	42.3 ± 17.9	0.068
Colo320DM	wild-type	102 ± 6.73	54.9 ± 4.56	54.9 ± 5.46	1.0
SNU-C1	wild-type	83.0 ± 11.4	107 ± 20.0	68.0 ± 15.9	0.023

From between three and seven independent experiments, each at least with triplicate setups, mean ± SD cell viability values were calculated in percentage of values from the corresponding controls (vehicle-treated cells). Treatments (24-h incubations): ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), combo-Rx (10 μM of both compounds in combination). Difference in values from cells given AZD8055 or combo-Rx was compared by two-tailed Student’s t-test. Mutation status is indicated for each cell line

ISSN: 1471-2407